Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts  

作　　者：Jun Sun Joerg Ermann Ningning Niu Guang Yan Yang Yang Yujiang Shi Weiguo Zou 

机构地区：[1]State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences,University of Chinese Academy of Sciences [2]Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital,Harvard Medical School [3]Newborn Medicine Division, Boston Children's Hospital and Department of Cell Biology, Harvard Medical School

出　　处：《Bone Research》2018年第3期226-237,共12页骨研究（英文版）

基　　金：supported in part by grants from 973 Program from the Chinese Ministry of Science and Technology (MOST) [2014CB964704, 2015CB964503];the National Natural Science Foundation of China (NSFC) [31371463];the "1000 Young Talents Program of China" and "the National Science Fund for Excellent Young Scholars" (NSFC) [81322027]

摘　　要：Multiple regulatory mechanisms control osteoblast differentiation and function to ensure unperturbed skeletal formation and remodeling. In this study we identify histone lysine-specific demethylase 1(LSD1/KDM1 A) as a key epigenetic regulator of osteoblast differentiation. Knockdown of LSD1 promoted osteoblast differentiation of human mesenchymal stem cells(hMSCs)in vitro and mice lacking LSD1 in mesenchymal cells displayed increased bone mass secondary to accelerated osteoblast differentiation. Mechanistic in vitro studies revealed that LSD1 epigenetically regulates the expression of WNT7 B and BMP2. LSD1 deficiency resulted in increased BMP2 and WNT7 B expression in osteoblasts and enhanced bone formation, while downregulation of WNT7 B-and BMP2-related signaling using genetic mouse model or small-molecule inhibitors attenuated bone phenotype in vivo. Furthermore, the LSD1 inhibitor tranylcypromine(TCP) could increase bone mass in mice. These data identify LSD1 as a novel regulator of osteoblast activity and suggest LSD1 inhibition as a potential therapeutic target for treatment of osteoporosis.Multiple regulatory mechanisms control osteoblast differentiation and function to ensure unperturbed skeletal formation and remodeling. In this study we identify histone lysine-specific demethylase 1(LSD1/KDM1 A) as a key epigenetic regulator of osteoblast differentiation. Knockdown of LSD1 promoted osteoblast differentiation of human mesenchymal stem cells(hMSCs)in vitro and mice lacking LSD1 in mesenchymal cells displayed increased bone mass secondary to accelerated osteoblast differentiation. Mechanistic in vitro studies revealed that LSD1 epigenetically regulates the expression of WNT7 B and BMP2. LSD1 deficiency resulted in increased BMP2 and WNT7 B expression in osteoblasts and enhanced bone formation, while downregulation of WNT7 B-and BMP2-related signaling using genetic mouse model or small-molecule inhibitors attenuated bone phenotype in vivo. Furthermore, the LSD1 inhibitor tranylcypromine(TCP) could increase bone mass in mice. These data identify LSD1 as a novel regulator of osteoblast activity and suggest LSD1 inhibition as a potential therapeutic target for treatment of osteoporosis.

关 键 词：LSD1/KDM1A HMSCS 

分 类 号：R[医药卫生]